EngiChem Life Sciences (CEO Ki-Young Son) announced on the 11th that it has acquired a US material patent for a novel immunomodulator, ‘1,2-diacylglycerol compound’ from the United States Patent and Trademark Office (USPTO).
The '1,2-diacylglycerol compound' recently patented by Engichem Life Sciences is a substance that can control the overexpression of cytokines (IL-4, IL-6, etc.) that cause inflammatory responses and chemokines (CXCL8, etc.) involved in the movement of inflammatory cells. It is a new immunomodulatory substance that can be used to prevent and treat various immune diseases such as bacterial or viral infections, acute and chronic inflammatory lung diseases, pneumonia, autoimmune diseases, allergic diseases, and cancer.
Immune diseases are mainly caused by abnormal immune function reactions and are currently treated with immunosuppressants. However, immunosuppressants can lower the body's immunity and cause other health problems, so it is important to control the body's immune function by appropriately stimulating immune cells through immunomodulatory substances, thereby increasing the ability to defend against diseases and minimizing side effects caused by immune overactivity.
With this US patent registration, EngiChem Lifesciences has secured the rights to its ‘novel 1,2-diacylglycerol immunomodulator’ in Korea (KR), the United States (US), Europe (EP), Japan (JP), China (CN), and India (IN).
An official from EngiChem Life Sciences stated, “This patent acquisition is significant as it is the result of our continued efforts to expand our new drug pipeline in the immune field through new substance discovery and efficacy research. The new patent is a follow-up immune-modulating substance following EC-18, and we expect it to become a key substance that can expand our new drug pipeline in the immune disease field by confirming the immune-modulating efficacy of the data accumulated through patent registration.”
- See more related articles
You must be logged in to post a comment.